|Diagram of a normal heart (left) and a heart with hypertrophic (increased thickness) cardiomyopathy (right). Image credit the American Heart Association.|
The findings will be published online Tuesday in The Lancet to coincide with a presentation at the European Society of Cardiology Congress 2013 meeting in Amsterdam. The National Heart, Lung, and Blood Institute (NHLBI) and the Children’s Cardiomyopathy Foundation supported this research.
Hypertrophic cardiomyopathy, a type of pediatric cardiomyopathy (diseases of the heart muscle) with varied causes and outcomes, is characterized by increased thickness (hypertrophy) of the heart wall.
HCM is rare, with fewer than one out of 100,000 children (ages birth to 18 years old) diagnosed annually in the United States. The condition is more frequently diagnosed in infants (under the age of one year), with 2 to 3 out of every 100,000 identified each year.
Researchers from the University of Miami Miller School of Medicine, along with colleagues from other institutions, sought to better understand how risk factors at the time of HCM diagnosis are predictors of death or the need to be added to a heart transplantation waiting list. They spent 19 years amassing data on more than 1,000 affected children at 98 pediatric cardiology centers in the U.S. and Canada through the NHLBI-funded Pediatric Cardiomyopathy Registry.
Researchers found that children with HCM caused by inborn errors of metabolism had the lowest rate of transplant-free survival within two years after diagnosis (43 percent). At two years after diagnosis, the rate of transplant-free survival was 55 percent for children with a mixed version of the disease that included thickening of the heart walls and enlargement and weakening of the heart and 62 percent for those with a restrictive form of the disease characterized by both a thickening and hardening of the heart walls. Children diagnosed after age one year with hypertrophic cardiomyopathy of unknown cause had the most favorable outcome, a 97 percent rate of transplant-free survival.
Infants and children who had two or more of the following risk factors at HCM diagnosis (depending on the cause of HCM) — lower weight or body size, female gender, diagnosis during infancy, congestive heart failure, and abnormal heart function — had an increased risk of poor outcomes (death or need for immediate heart transplantation).
These findings are expected to assist clinicians in identifying which children are likely to have the worst outcomes (death or need for immediate heart transplantation) within two years of diagnosis, thereby enabling medical teams, genetic counselors, and family planners to jointly and quickly determine the best treatment approach.
WHO: Gail Pearson, M.D., Sc.D., a pediatric cardiologist and director of the Adult and Pediatric Cardiac Research Program at the NHLBI, and Jonathan Kaltman, M.D., a pediatric cardiologist and chief of the Heart Development and Structural Diseases Branch in the NHLBI’s Division of Cardiovascular Sciences, are available to comment on the findings and implications of this research.
For Dr. Pearson’s complete bio, please visit: http://www.nhlbi.nih.gov/news/spokespeople/pearson-gail.html
For Dr. Kaltman’s complete bio, please visit: http://www.nhlbi.nih.gov/news/spokespeople/kaltman-jonathan.html
CONTACT: For more information or to schedule an interview, please contact the NHLBI Communications Office at 301-496-4236 or firstname.lastname@example.org.